Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2143714 | 0.81 | POLB (0.56) | ALDH1A1EGLN1HTTPOLBSMN1; SMN2 | |
| SCHEMBL16735559 | 0.80 | HSP90AA1 (0.40) | ALDH1A1HTTPOLBSMN1; SMN2MAPT | |
| SCHEMBL2143791 | 0.79 | POLB (0.53) | ALDH1A1HTTPOLBSMN1; SMN2MAPT | |
| SCHEMBL2232317 | 0.77 | ALDH1A1 (0.47) | ALDH1A1BCHEEGLN1POLBSMN1; SMN2 | |
| SCHEMBL2143801 | 0.77 | ALDH1A1 (0.47) | ALDH1A1BCHEEGLN1PRMT5WDR77 | |
| SCHEMBL2144029 | 0.77 | PDK1 (0.58) | ALDH1A1 | |
| SCHEMBL2143724 | 0.74 | ALDH1A1 (0.58) | ALDH1A1EGLN1HTTPRMT5WDR77 | |
| SCHEMBL2143736 | 0.74 | CTSB (0.60) | ALDH1A1BCHEEGLN1MAPT | |
| SCHEMBL2143911 | 0.73 | ALDH1A1 (0.57) | ALDH1A1BCHEEGLN1PRMT5WDR77 | |
| SCHEMBL2143753 | 0.73 | TP53 (0.64) | ALDH1A1BCHEEGLN1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2519505-B1 | TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF | POLICHEM SA (LU) | 2015-05-27 | — | — | EP | claimed |
| US-8729098-B2 | Tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof | POLICHEM SA (LU) | 2014-05-20 | — | — | US | claimed |
| US-20120309751-A1 | TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF | POLICHEM SA (LU) | 2012-12-06 | — | — | US | claimed |
| EP-2519505-A1 | NEW TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF | Polichem SA (LU) | 2012-11-07 | — | — | EP | claimed |
| EP-2345643-A1 | New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof | POLICHEM S.A. (LU) | 2011-07-20 | — | — | EP | claimed |
| WO-2011080264-A1 | NEW TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF | POLICHEM S.A. (LU) | 2011-07-07 | — | — | WO | claimed |
| EP-2519505-B1 | TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF | POLICHEM SA (LU) | 2015-05-27 | — | — | EP | disclosed |
| US-8729098-B2 | Tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof | POLICHEM SA (LU) | 2014-05-20 | — | — | US | disclosed |
| US-8729098-B2 | Tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof | POLICHEM SA (LU) | 2014-05-20 | — | — | US | disclosed |
| US-8729098-B2 | Tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof | POLICHEM SA (LU) | 2014-05-20 | — | — | US | disclosed |
| US-20120309751-A1 | TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF | POLICHEM SA (LU) | 2012-12-06 | — | — | US | disclosed |
| US-20120309751-A1 | TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF | POLICHEM SA (LU) | 2012-12-06 | — | — | US | disclosed |
| US-20120309751-A1 | TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF | POLICHEM SA (LU) | 2012-12-06 | — | — | US | disclosed |
| EP-2345643-A1 | New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof | POLICHEM S.A. (LU) | 2011-07-20 | — | — | EP | disclosed |
| WO-2011080264-A1 | NEW TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF | POLICHEM S.A. (LU) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309751-A1 | TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF | TUBA8, SUCLG1, TUBB8 | ALDH1A1 931/4885BCHE 747/4885EGLN1 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.